News
EXAS
104.91
0.00%
0.00
BTIG Suspends Neutral Rating on Exact Sciences
Benzinga · 03/24 09:59
*News On Exact Sciences Corp. (EXAS) Now Under ABT
Dow Jones · 03/23 21:08
Exact Sciences Completed Acquisition and Delisting by Abbott
TipRanks · 03/23 13:44
Weekly Report: what happened at EXAS last week (0316-0320)?
Weekly Report · 03/23 09:45
Exact Sciences Nears Completion of Abbott Acquisition Deal
TipRanks · 03/20 13:29
Abbott Announces Acquisition Of Exact Sciences To Close March 23rd; Exact Sciences Stockholders To Receive $105/Share
Benzinga · 03/20 13:05
*Abbott Labs: Received All Regulatory Clearances for Exact Sciences Buy >ABT EXAS
Dow Jones · 03/20 13:01
How Is Quest Diagnostics’ Stock Performance Compared to Other Healthcare Stocks?
Barchart · 03/19 05:38
Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026
Barchart · 03/17 15:31
Weekly Report: what happened at EXAS last week (0309-0313)?
Weekly Report · 03/16 09:45
Weekly Report: what happened at EXAS last week (0302-0306)?
Weekly Report · 03/09 09:46
3 Cash-Producing Stocks We Approach with Caution
Barchart · 03/06 04:44
Amalgam Announces Privia Health-Led Colorectal Cancer Screening Program Demonstrates 84% Screening Rates In 2024, Surpassing 80% Goal
Benzinga · 03/03 15:05
Weekly Report: what happened at EXAS last week (0223-0227)?
Weekly Report · 03/02 09:45
December 18th Options Now Available For EXACT Sciences (EXAS)
NASDAQ · 02/27 15:43
Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time
NASDAQ · 02/25 14:40
Abbott eyes $20B bond sale to fund purchase of Exact Sciences - report
Seeking Alpha · 02/23 16:10
'Abbott Laboratories Kicks Off Bond Sale for Exact Sciences Deal' - Bloomberg
Benzinga · 02/23 14:18
Weekly Report: what happened at EXAS last week (0216-0220)?
Weekly Report · 02/23 09:45
Exact Sciences Shareholders Approve Merger with Abbott Laboratories
TipRanks · 02/20 22:23
More
Webull provides a variety of real-time EXAS stock news. You can receive the latest news about Exact Sciences Corp through multiple platforms. This information may help you make smarter investment decisions.
About EXAS
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.